Vinblastine sulfate (Synonyms: Vincaleukoblastine sulfate salt)

Name: Vinblastine sulfate
Brand: MedChemExpress
SKU: HY-13780
Rating: 5.0 (16 reviews)

Cat. No.: HY-13780 Purity: 99.83%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC₅₀ of 8.9 μM.

For research use only. We do not sell to patients.

CAS No. : 143-67-9

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of Vinblastine sulfate:

Vinblastine sulfate (Standard) In-stock

16 Publications Citing Use of MCE Vinblastine sulfate

IHC

Cell Proliferation/Viability Assay

: Vinblastine sulfate purchased from MedChemExpress. Usage Cited in: Clin Epigenetics. 2025 May 6;17(1):77. [Abstract]; CaCO2 cells were treated with 8.52 μmol vinblastine, 1.68 μmol docetaxel, 5.49 μmol gemcitabine, 10.94 μmol vincristine, and 11.71 μmol daporinad or DMSO for 48 h. HCT116 cells were treated with 4.87 μmol vinblastine, 1.68 μmol docetaxel, 5.49 μmol gemcitabine, 10.94 μmol vincristine, and 11.71 μmol daporinad or DMSO for 48 h. Flow cytometry was used to quantify the proportion of LGR5+ subpopulation in CaCO2 and HCT116 cells.

: Vinblastine sulfate purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2021 Aug 9;17(8):e1009838. [Abstract]; HepAD38 cells were treated with Nocodazole or Vinblastine for 24 h before fixation and processed for HBV pgRNA (A) or (-) DNA (B), HBcAg and α-tubulin detection. White arrows indicate the pgRNA or (-) DNA were colocalized with HBcAg. Scale bar, 4 μm.

: Vinblastine sulfate purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2021 Aug 9;17(8):e1009838. [Abstract]; Cell viability under Nocodazole and Vinblastine treatment after 24 h was determined by CCK8 assay.

: Vinblastine sulfate purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2021 Aug 9;17(8):e1009838. [Abstract]; HepAD38 cells were treated with Nocodazole and Vinblastine for 24 h. Intracellular distribution of HBV (-) DNA and preS1 were visualized by FISH and immunofluorescence. White arrows indicate (-) DNA puncta colocalizing with preS1. Scale bar, 4 μm.

: Vinblastine sulfate purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2021 Jan-Jun:296:100525.; A, valnemulin and vinblastine at the dose range of 1 to 10 μM demonstrated a significantly enhanced HDR rate in 293T cells using the unmodified CRISPR system and donor for EGFP KI in the GAPDH locus shown in Figure 1A. B, combinational treatment of the two small molecules showed a further enhanced HDR rate compared with using either of them alone.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC₅₀ of 8.9 μM.

IC₅₀ & Target

IC50: 8.9 μM(nAChR)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	7.2 μM Compound: Vinblastine sulfate	Cytotoxicity against human A375 cells after 48 hrs by SRB assay Cytotoxicity against human A375 cells after 48 hrs by SRB assay	[PMID: 19467877]
A549	IC₅₀	0.002 μg/mL Compound: Vinblastin sulfate	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 9214732]
A549	IC₅₀	2.36 μM Compound: Vinblastine sulphate	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay Antiproliferative activity against human A549 cells after 48 hrs by MTS assay	[PMID: 22546674]
A549	IC₅₀	67.3 μM Compound: Vinblastine sulfate	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 19467877]
ACHN	IC₅₀	22.7 μM Compound: Vinblastine sulfate	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 19467877]
BXPC-3	IC₅₀	1.13 μM Compound: Vinblastine sulphate	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay	[PMID: 22546674]
C32	IC₅₀	3 μM Compound: Vinblastine sulfate	Cytotoxicity against human C32 cells after 48 hrs by SRB assay Cytotoxicity against human C32 cells after 48 hrs by SRB assay	[PMID: 19467877]
COLO 320	EC₅₀	< 0.08 μM Compound: 1	In vitro concentration required to kill 50% of COLO 320 human colorectal carcinoma cell line In vitro concentration required to kill 50% of COLO 320 human colorectal carcinoma cell line	[PMID: 12361397]
COR-L23	IC₅₀	45.5 μM Compound: Vinblastine sulfate	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay	[PMID: 19467877]
CWR22R	IC₅₀	1 nM Compound: Vinblastine sulfate	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38237151]
Caco-2	IC₅₀	69 μM Compound: Vinblastine sulfate	Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay	[PMID: 19467877]
DU-145	IC₅₀	4.25 μM Compound: Vinblastine sulphate	Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay	[PMID: 22546674]
HCT-116	IC₅₀	1 nM Compound: Vinblastine sulfate	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38237151]
HCT-8	IC₅₀	0.005 μg/mL Compound: Vinblastin sulfate	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 9214732]
HT-29	IC₅₀	0.55 μM Compound: Vinblastine	Cytotoxicity against human HT-29 cells after 48 hrs by MTS assay Cytotoxicity against human HT-29 cells after 48 hrs by MTS assay	[PMID: 21920762]
HT-29	IC₅₀	11.18 μM Compound: Vinblastine sulphate	Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay	[PMID: 22546674]
HepG2	IC₅₀	0.019 μM Compound: Vinblastine sulfate	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23708010]
HepG2	IC₅₀	0.056 μM Compound: Vinblastine sulfate	Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23708010]
HepG2	IC₅₀	0.16 μM Compound: Vinblastine sulphate	Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay	[PMID: 22546674]
K562	IC₅₀	0.001 μM Compound: 1	Antiproliferative activity against human K562 cell line Antiproliferative activity against human K562 cell line	[PMID: 17181164]
K562	IC₅₀	0.001 μM Compound: 1	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 20537765]
K562	IC₅₀	0.001 μM Compound: 1	Cell growth inhibition of human K562 cells after 48 hrs Cell growth inhibition of human K562 cells after 48 hrs	[PMID: 20546980]
K562	IC₅₀	0.001 μM Compound: 1 (Vinblastine sulfate)	In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth	[PMID: 12852768]
K562	IC₅₀	0.001 μM Compound: Vinblastine sulphate	Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer	[PMID: 21705223]
K562	IC₅₀	0.001 μM Compound: vinblastine sulfate	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 17973361]
K562	IC₅₀	0.001 μM Compound: vinblastine sulfate	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 19220018]
K562	IC₅₀	0.001 μM Compound: vinblastine sulfate	Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis	[PMID: 21563750]
K562	IC₅₀	0.016 μM Compound: Vinblastine sulfate	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23708010]
K562	IC₅₀	0.13 μM Compound: 1	Inhibition of tubulin polymerization in human K562 cells Inhibition of tubulin polymerization in human K562 cells	[PMID: 20546980]
L6	ED₅₀	6.1 μM Compound: vinblastine sulphate	Cytotoxicity against human SCL6 cells by MTT assay Cytotoxicity against human SCL6 cells by MTT assay	[PMID: 12880314]
LNCaP	EC₅₀	0.5 μM Compound: 1	In vitro concentration required to kill 50% of LNCaP human prostate cancer cell line In vitro concentration required to kill 50% of LNCaP human prostate cancer cell line	[PMID: 12361397]
LNCaP	IC₅₀	29.3 μM Compound: Vinblastine sulfate	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	0.007 μM Compound: Vinblastine sulfate	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23708010]
MCF7	IC₅₀	24.08 μM Compound: Vinblastine sulphate	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 22546674]
MDA-MB-231	IC₅₀	0.0083 μM Compound: Vinblastine sulfate	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23708010]
MDA-MB-231	IC₅₀	31.52 μM Compound: Vinblastine sulphate	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay	[PMID: 22546674]
NUGC-4	ED₅₀	5.3 μM Compound: vinblastine sulphate	Cytotoxicity against human NUGC4 cells by MTT assay Cytotoxicity against human NUGC4 cells by MTT assay	[PMID: 12880314]
SK-MEL-5	IC₅₀	1.74 μM Compound: Vinblastine sulphate	Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay	[PMID: 22546674]
T47D	EC₅₀	< 0.08 μM Compound: 1	In vitro concentration required to kill 50% of T47D human breast ductal carcinoma cell line In vitro concentration required to kill 50% of T47D human breast ductal carcinoma cell line	[PMID: 12361397]
UACC-903	IC₅₀	1.65 μM Compound: Vinblastine	Cytotoxicity against human UACC903 cells after 48 hrs by MTS assay Cytotoxicity against human UACC903 cells after 48 hrs by MTS assay	[PMID: 21920762]

In Vitro

Vinblastine does not depolymerize spindle microtubules, yet it powerfully blocks mitosis (for example, IC₅₀ 0.8 nM in HeLa cells) and cells die by apoptosis^[2]. In NB4 cells, vinblastine produces alteration of p53 and DNA fragmentation. Vinblastine treatment has an antiproliferative effect via the induction of apoptosis producing Bax/Bcl-2 imbalance. Vinblastine treatment suppresses NFκB expression and depresses NFκB-DNA binding activity while maintaining JNK activation that subsequently results in apoptotic response through caspase-dependent pathway^[3]. Vinblastine is found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vinblastine is a widely used anticancer drug with undesired side effects. Its conjugation with carrier molecules could be an efficient strategy to reduce these side effects^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

909.05

Formula

C₄₆H₆₀N₄O₁₃S

CAS No.

143-67-9

Appearance

Solid

Color

White to off-white

SMILES

[H][C@@]12C[C@@](C3=C(OC)C=C(N([C@]4([H])[C@@]56[C@]7([H])[C@](C=CCN7CC6)(CC)[C@@H](OC(C)=O)[C@@]4(C(OC)=O)O)C)C5=C3)(C(OC)=O)C(NC8=C9C=CC=C8)=C9CC[N@](C2)C[C@](O)(CC)C1.OS(=O)(O)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (55.00 mM; Need ultrasonic)

DMSO : ≥ 44 mg/mL (48.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1000 mL	5.5002 mL	11.0005 mL
5 mM	0.2200 mL	1.1000 mL	2.2001 mL
10 mM	0.1100 mL	0.5500 mL	1.1000 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.75 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.75 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.75 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 50 mg/mL (55.00 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.83%

Select Batch:

Data Sheet (283 KB) SDS (419 KB)

COA (259 KB) RP-HPLC (223 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. McKay DB, et al. Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6. [Content Brief]

[2]. Pandya P, et al. Molecular recognition pattern of cytotoxic alkaloid vinblastine with multiple targets. J Mol Graph Model. 2014 Nov;54:1-9. [Content Brief]

[3]. Calvi?o E, et al. JNK and NFκB dependence of apoptosis induced by vinblastine in human acute promyelocytic leukaemia cells. Cell Biochem Funct. 2015 Jun;33(4):211-9. [Content Brief]

[4]. Selimovic D, et al. Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms. Apoptosis. 2013 Aug;18(8):980-97. [Content Brief]

[5]. Bánóczi Z, et al. Synthesis and in vitro antitumor effect of vinblastine derivative-oligoarginine conjugates. Bioconjug Chem. 2010 Nov 17;21(11):1948-55. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.1000 mL	5.5002 mL	11.0005 mL	27.5012 mL
	5 mM	0.2200 mL	1.1000 mL	2.2001 mL	5.5002 mL
	10 mM	0.1100 mL	0.5500 mL	1.1000 mL	2.7501 mL
	15 mM	0.0733 mL	0.3667 mL	0.7334 mL	1.8334 mL
	20 mM	0.0550 mL	0.2750 mL	0.5500 mL	1.3751 mL
	25 mM	0.0440 mL	0.2200 mL	0.4400 mL	1.1000 mL
	30 mM	0.0367 mL	0.1833 mL	0.3667 mL	0.9167 mL
	40 mM	0.0275 mL	0.1375 mL	0.2750 mL	0.6875 mL
H₂O	50 mM	0.0220 mL	0.1100 mL	0.2200 mL	0.5500 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Vinblastine sulfate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vinblastine143-67-9VincaleukoblastineMicrotubule/TubulinnAChRAutophagyNicotinic acetylcholine receptorsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Vinblastine sulfate (Synonyms: Vincaleukoblastine sulfate salt)

Customer Review

Other Forms of Vinblastine sulfate:

Vinblastine sulfate Related Antibodies

16 Publications Citing Use of MCE Vinblastine sulfate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Vinblastine sulfate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vinblastine sulfate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report